Cd70 Expression in Cutaneous T Cell Lymphoma (Ctcl) Patients and Mechanisms of Action of Argx‐110 in Skin: Histopathological and Clinical Data

Hultberg, Anna; Gandini, Domenica; Bagot, M.; Maerevoet, Marie; Zwaenepoel, Karen; Winne, Koen De; Morschhauser, F.; Moshir, Mahan; Rompaey, Luc Van; Silence, Karen; Haard, Hans de; Pauwels, Patrick; Leupin, Nicolas; Pileri, S

doi:10.1002/hon.2438_148

Cited by 4 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…T cell lymphoma Constitutive CD27 and CD70 expression has also been detected on T cell neoplasia such as anaplastic large cell lymphoma [7,67], peripheral T cell lymphoma [7], cutaneous T cell lymphoma [68][69][70][71][72], adult T cell leukemia/lymphoma [73][74][75] and extranodal NK/T cell lymphoma [7,76,77]. On the contrary, only CD70 expression is observed on chronic active Epstein-Barr virus associated T cell lymphoma (a rare complication of latent Epstein-Barr virus infection) [78] and T cell acute lymphoblastic leukemia [79].…”

Section: The Cd70-cd27 Axis In Oncology Expression On Hematologic Mal...mentioning

confidence: 99%

The CD70-CD27 axis in oncology: the new kids on the block

Flieswasser

Eynde

Audenaerde³

et al. 2022

J Exp Clin Cancer Res

View full text Add to dashboard Cite

The immune checkpoint molecule CD70 and its receptor CD27 are aberrantly expressed in many hematological and solid malignancies. Dysregulation of the CD70-CD27 axis within the tumor and its microenvironment is associated with tumor progression and immunosuppression. This is in contrast to physiological conditions, where tightly controlled expression of CD70 and CD27 plays a role in co-stimulation in immune responses. In hematological malignancies, cancer cells co-express CD70 and CD27 promoting stemness, proliferation and survival of malignancy. In solid tumors, only expression of CD70 is present on the tumor cells which can facilitate immune evasion through CD27 expression in the tumor microenvironment. The discovery of these tumor promoting and immunosuppressive effects of the CD70-CD27 axis has unfolded a novel target in the field of oncology, CD70.In this review, we thoroughly discuss current insights into expression patterns and the role of the CD70-CD27 axis in hematological and solid malignancies, its effect on the tumor microenvironment and (pre)clinical therapeutic strategies.

show abstract

Section: The Cd70-cd27 Axis In Oncology Expression On Hematologic Mal...mentioning

confidence: 99%

The CD70-CD27 axis in oncology: the new kids on the block

Flieswasser

Eynde

Audenaerde³

et al. 2022

J Exp Clin Cancer Res

View full text Add to dashboard Cite

show abstract

“…ARGX-110 has been administered to 16 patients with CTCL with disease control and response seen in 9 patients, including 3 PR. Treatment has been well tolerated with no grade 3 toxicities noted to date (59, 60).…”

Section: Experimental Antibody Therapiesmentioning

confidence: 97%

Antibody-Directed Therapies: Toward a Durable and Tolerable Treatment Platform for CTCL

Khan

Sawas

2019

Front. Oncol.

View full text Add to dashboard Cite

Cutaneous T-cell lymphomas (CTCL) are a rare group of heterogeneous disorders characterized by cutaneous involvement of monoclonal T-lymphocytes. Although indolent at early stages, CTCL can confer significant morbidity, and mortality when advanced. There is an unmet need for tolerable and durable treatments with antibodies recently gaining promise. Here we review approved systemic therapies and discuss select antibodies in development.

show abstract

“…This study not only confirms that CD26 is an effective target for the treatment of T-cell malignancies but also highlights the potential of CAR-Tcell therapies employing different costimulatory domains to enhance therapeutic efficacy, especially the remarkable anticancer efficacy of third-generation CAR-T-cell therapies, which provides important insights into understanding the mechanism and optimization of therapeutic regimens for CAR-T-cell therapies and provides a new direction for future therapeutic strategies. CD70 CD70, a type 2 transmembrane glycoprotein belonging to the tumor necrosis factor (TNF) ligand family, was found to be highly expressed in malignant hematopoietic stem cells and solid tumors and constitutively expressed in activated T-cell leukemias and lymphomas in previous studies, indicating its potential as an immunotherapeutic target [72]. In the COBALT-LYM study (NCT04502446) [37], a CAR-T-cell product (CTX130) targeting CD70 was developed to edit TRAC, β2-microglobulin, and CD70 using CRISPR-Cas9 technology to reduce CAR-T-cell self-interaction and improve therapeutic safety and efficacy.…”

Section: Cd26mentioning

confidence: 99%

“…CD70, a type 2 transmembrane glycoprotein belonging to the tumor necrosis factor (TNF) ligand family, was found to be highly expressed in malignant hematopoietic stem cells and solid tumors and constitutively expressed in activated T-cell leukemias and lymphomas in previous studies, indicating its potential as an immunotherapeutic target [ 72 ]. In the COBALT-LYM study (NCT04502446) [ 37 ], a CAR-T-cell product (CTX130) targeting CD70 was developed to edit TRAC, β2-microglobulin, and CD70 using CRISPR-Cas9 technology to reduce CAR-T-cell self-interaction and improve therapeutic safety and efficacy.…”

Section: Exploration Of Car-t-cell Therapy Targets In T-cell Malignan...mentioning

confidence: 99%

Advances in CAR-T-cell therapy in T-cell malignancies

Zheng,

Zhu,

Xiao

2024

J Hematol Oncol

View full text Add to dashboard Cite

Significant advances have been made in chimeric antigen receptor T (CAR-T)-cell therapy for the treatment of recurrent or refractory B-cell hematologic malignancies. However, CAR-T-cell therapy has not yet achieved comparable success in the management of aggressive T-cell malignancies. This article reviews the challenges of CAR-T-cell therapy in treating T-cell malignancies and summarizes the progress of preclinical and clinical studies in this area. We present an analysis of clinical trials of CAR-T-cell therapies for the treatment of T-cell malignancies grouped by target antigen classification. Moreover, this review focuses on the major challenges encountered by CAR-T-cell therapies, including the nonspecific killing due to T-cell target antigen sharing and contamination with cell products during preparation. This review discusses strategies to overcome these challenges, presenting novel therapeutic approaches that could enhance the efficacy and applicability of CAR-T-cell therapy in the treatment of T-cell malignancies. These ideas and strategies provide important information for future studies to promote the further development and application of CAR-T-cell therapy in this field.

show abstract

Cd70 Expression in Cutaneous T Cell Lymphoma (Ctcl) Patients and Mechanisms of Action of Argx‐110 in Skin: Histopathological and Clinical Data

Cited by 4 publications

References 0 publications

The CD70-CD27 axis in oncology: the new kids on the block

The CD70-CD27 axis in oncology: the new kids on the block

Antibody-Directed Therapies: Toward a Durable and Tolerable Treatment Platform for CTCL

Advances in CAR-T-cell therapy in T-cell malignancies

Contact Info

Product

Resources

About